Zepbound

Eli Lilly blows past quarterly estimates, hikes outlook as Zepbound and Mounjaro sales skyrocket

Eli Lilly on Thursday reported first-quarter earnings and revenue that blew past estimates and hiked its full-year sales outlook by $2 billion, as demand for its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro spiked again. The pharmaceutical giant now expects 2026 revenue to come in between $82 billion and $85 billion, up from…

International News

FDA approves weight loss drug Zepbound to treat obstructive sleep apnea

Isaac Hammouch1 year ago03 mins

The Meals and Drug Administration has approved using Zepbound for adults with weight problems and reasonable to extreme obstructive sleep apnea. Getty Photographs/iStockphoto disguise caption toggle caption Getty Photographs/iStockphoto The burden loss drug Zepbound has grow to be the primary prescription remedy accepted to deal with obstructive sleep apnea. The Meals and Drug Administration on…

Gold and silver's historic rally could resume 'as fog of war lifts', market watchers say

Savannah Guthrie Returns to Today Show After Sudden Exit

Iran reviews U.S. proposal. And, Rubio to meet Pope Leo after Trump's criticism

Az Cohen, Believe Launch AZTEC Joint Venture, French Company’s First U.S. Label

The Paramount Merger Can (and Should) Be Stopped

Nigeria: Nigeria Police Repatriate Chinese Fugitive Over $245m Ponzi Scheme

Australian North set to be England selector

Lit Hub Daily: May 7, 2026

The ‘Perfect Storm’ Hanging Over Britain’s Public Debt

Higgins returns for Ireland to face Wales

Eli Lilly blows past quarterly estimates, hikes outlook as Zepbound and Mounjaro sales skyrocket

FDA approves weight loss drug Zepbound to treat obstructive sleep apnea